Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
about
Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation updateGenetics of Progressive Supranuclear PalsyTDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPTLeucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutationsClinical and pathological characteristics of LRRK2 G2019S patients with PD.α-Synuclein oligomers and clinical implications for Parkinson disease.Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.Tau protein modifications and interactions: their role in function and dysfunction.The neuropathology of genetic Parkinson's disease.Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.Parkinson's disease-associated DJ-1 mutations increase abnormal phosphorylation of tau protein through Akt/GSK-3β pathways.LRRK2 variation and dementia with Lewy bodies.Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase (LRRK2) G2019S mutation carriers.Pathological and Clinical Spectrum of Progressive Supranuclear Palsy: With Special Reference to Astrocytic Tau Pathology.Atypical tauopathy in a patient with LRRK2-G2019S mutation and tremor-dominant Parkinsonism.Parkinson's disease-associated PINK1 G309D mutation increases abnormal phosphorylation of Tau.
P2860
Q22252904-CEE33CA0-4723-4E2C-BB3F-74DAD1642941Q26785904-B844F1E6-62A7-4AF0-93B9-5D13BB842184Q26851112-EBBA856C-D240-4699-AAAC-BDA45FDE8F10Q33808789-0D09C47F-6BD1-4F5E-B1F8-D0CAC32B5DB9Q35004642-621122C2-BA5D-4C92-94C7-5793DB497C97Q35911042-D57327BB-030E-41F2-BE9D-3084B2BD2BC6Q36718306-C5935409-9C55-4AAD-A7B4-66725FC066E8Q37313530-33B74676-90D9-4B3A-932A-9F1CEE4989F7Q37684106-C1D47A02-90C5-4832-ABFA-C007A82F0054Q37997386-D9A96B98-1AB8-4C5F-9CE8-2C3887A18F96Q38738200-9BBB567A-6DB6-4148-AE3C-A5F6880C2F98Q39104616-7F13718F-4177-47DB-ACA5-EAEA49F19F97Q41655722-D5D9C52C-7856-43E7-8BCD-51BC4F5F7D25Q47161677-539B54D3-497C-4196-A183-17D5E9D05D98Q47619453-5A78FB71-F628-4F81-B08A-F3167A29142FQ47978229-4550A9BB-0031-4ED2-B2C0-1FCAF0FF1942Q48177425-DC9D1951-C567-4405-8C9A-9BB4F414A48CQ50262835-71706B7E-3639-4BD8-BA4B-12618276CA87Q54276344-E084F306-1B73-4D27-A0F3-AA25B67D8E65
P2860
Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Screening for the LRRK2 G2019S ...... totemporal lobar degeneration.
@en
Screening for the LRRK2 G2019S ...... totemporal lobar degeneration.
@nl
type
label
Screening for the LRRK2 G2019S ...... totemporal lobar degeneration.
@en
Screening for the LRRK2 G2019S ...... totemporal lobar degeneration.
@nl
prefLabel
Screening for the LRRK2 G2019S ...... totemporal lobar degeneration.
@en
Screening for the LRRK2 G2019S ...... totemporal lobar degeneration.
@nl
P2093
P50
P1476
Screening for the LRRK2 G2019S ...... totemporal lobar degeneration.
@en
P2093
Adriana Cardozo
Albert Lladó
Carles Gaig
Esteban Muñoz
Maria Jesús Rey
Maria José Martí
P356
10.1016/J.JNS.2008.02.010
P577
2008-03-19T00:00:00Z